Core Insights - SurModics reported revenue of $29.57 million for the quarter ended June 2025, a decrease of 2.6% year-over-year, but exceeded the Zacks Consensus Estimate by 4.29% [1] - The company achieved an EPS of $0.06, a significant improvement from -$0.27 in the same quarter last year, resulting in an EPS surprise of 128.57% compared to the consensus estimate of -$0.21 [1] Revenue Breakdown - Product sales amounted to $16.76 million, surpassing the average estimate of $15.69 million, but reflecting a year-over-year decline of 4.6% [4] - Revenue from research, development, and other sources was $3.15 million, exceeding the average estimate of $2.37 million, marking a year-over-year increase of 35.7% [4] - Royalties and license fees generated $9.66 million, slightly below the estimated $10.2 million, representing a year-over-year decrease of 7.7% [4] Stock Performance - SurModics shares have returned +12.9% over the past month, outperforming the Zacks S&P 500 composite's +1.9% change [3] - The stock currently holds a Zacks Rank 5 (Strong Sell), indicating potential underperformance relative to the broader market in the near term [3]

Group 1 - European Wax Center, Inc. (EWCZ) is expected to report quarterly earnings of $0.19 per share, a 26.7% increase year-over-year, while revenues are forecasted at $56.93 million, reflecting a 4.9% decrease compared to the same period last year [1] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating that analysts have collectively reassessed their initial estimates during this period [2] - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock price performance [3] Group 2 - Analysts project 'Revenue- Marketing fees' to reach $7.79 million, a decrease of 4.3% from the prior-year quarter [5] - 'Revenue- Royalty fees' is estimated at $14.02 million, suggesting a 3.1% year-over-year decline [5] - 'Revenue- Product sales' is expected to be $31.29 million, indicating a 7.8% decrease year-over-year [5] - 'Revenue- Other revenue' is projected at $3.22 million, reflecting a 3.7% decline from the previous year [6] - The consensus for 'Ending center count' is 1,054, down from 1,059 in the same quarter last year [6] Group 3 - Over the past month, European Wax Center shares have declined by 23.5%, while the Zacks S&P 500 composite has increased by 1.9% [7] - EWCZ holds a Zacks Rank 3 (Hold), suggesting that its performance is likely to align with the overall market in the near future [7]

Where Food Comes From, Inc. Reports 2025 Second Quarter Financial Results Second Quarter Highlights – 2025 vs. 2024 In Subsequent Event, Company Sells Interest in Progressive Beef for $1.8 Million in Cash and Return of 12,585 Shares of WFCF Common Stock, Further Reducing Number of Outstanding Shares CASTLE ROCK, Colorado – August 7, 2025 – Where Food Comes From, Inc. (WFCF) (Nasdaq: WFCF), the most trusted resource for independent, third-party verification of food production practices in North America, toda ...

Core Insights - SurModics reported a revenue of $28.09 million for the quarter ended March 2025, reflecting a decline of 12.1% year-over-year and an earnings per share (EPS) of -$0.13, compared to $0.07 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of $30.77 million by 8.73%, and the EPS was significantly below the consensus estimate of -$0.06, resulting in an EPS surprise of -116.67% [1] Revenue Breakdown - Product sales amounted to $14.99 million, which is a decrease of 17.2% year-over-year and below the average estimate of $17.46 million from two analysts [4] - Revenue from research, development, and other sources was $3.19 million, exceeding the two-analyst average estimate of $2.41 million, marking a year-over-year increase of 30.1% [4] - Royalties and license fees generated $9.91 million, slightly below the average estimate of $10.37 million from two analysts, representing a year-over-year decline of 13.2% [4] Stock Performance - Over the past month, shares of SurModics have returned +0.1%, contrasting with a -0.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]